Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and Hypertension

Rubio-Guerra, Alberto Francisco; Treviño-Gomezharper, Carlos; Rodríguez-López, Leticia; Vargas-Ayala, Germán; Lozano-Nuevo, José Juan; Arceo-Navarro, Adalberto

doi:10.2165/00044011-200222080-00006

Cited by 12 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group found that the combination of an ACEI with a calcium antagonist was more effective than ACEI monotherapy in decreasing proteinuria and slowing down renal deterioration in normotensive type 2 diabetic patients [27], and in hypertensive patients who do not respond to monotherapy [28].…”

Section: Nephroprotective Effectmentioning

confidence: 95%

Combination Therapy in the Treatment of Hypertension

Battegay¹,

Bakris²,

Lip³

2005

Hypertension

View full text Add to dashboard Cite

Hypertension is a major preventable risk factor for atherosclerosis and ischemic heart disease. Although modern and effective antihypertensive drugs are available, most patients remain with a suboptimal blood pressure control. Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals -recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets. In this review, we analyse the latest information available regarding the treatment of hypertension with combination therapy.

show abstract

Section: Nephroprotective Effectmentioning

confidence: 95%

Combination Therapy in the Treatment of Hypertension

Battegay¹,

Bakris²,

Lip³

2005

Hypertension

View full text Add to dashboard Cite

show abstract

“…Results from a large-scale cardiovascular and renal function markers as surrogate endpoints survey found that treatment with a fixed-dose combination of a β-to assess the effects of these agents on target organ damage (table blocker/diuretic improved BP control, while maintaining the con-IV). [49,[91][92][93][94][95][96][97][98][99] These studies show that ACE inhibitor/CCB and venience of once-daily administration and without added adverse ACE inhibitor/diuretic combinations, namely trandolapril/vereffects relative to monotherapy. [86] However, β-blocker/diuretic apamil [91][92][93][94][95] and perindopril/indapamide, [49,96,98] reverse LVH and combinations often have an additive, rather than synergistic, efimprove renal function.…”

Section: Fixed-dose Combinations and Target Organ Damagementioning

confidence: 99%

“…[49,[91][92][93][94][95][96][97][98][99] These studies show that ACE inhibitor/CCB and venience of once-daily administration and without added adverse ACE inhibitor/diuretic combinations, namely trandolapril/vereffects relative to monotherapy. [86] However, β-blocker/diuretic apamil [91][92][93][94][95] and perindopril/indapamide, [49,96,98] reverse LVH and combinations often have an additive, rather than synergistic, efimprove renal function. Similarly, amlodipine besylate/benazepril fect; antihypertensive combinations with synergistic effects allow was found to improve LV physiology [98] and delapril/indapamide for lower doses of component drugs to achieve similar BP reducincreased the GFR in patients with hypertension.…”

Section: Fixed-dose Combinations and Target Organ Damagementioning

confidence: 99%

Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage

Smith

2007

American Journal of Cardiovascular Drugs

View full text Add to dashboard Cite

Hypertension is a multifactorial disorder leading to pathophysiologic changes in target organs over time through diverse mechanisms. In addition, hypertension frequently resists control with monotherapy, necessitating combination therapy with two or more antihypertensive agents. Many currently available fixed-dose antihypertensive combinations combine drugs with different, but complementary, mechanisms of action to improve overall efficacy and tolerability. In addition, it is possible to select drug combinations whereby one drug offsets the negative effects of the other drug. Fixed-dose antihypertensive combinations may provide significant advantages over high-dose monotherapy, such as improved BP-lowering efficacy, reduced adverse event frequency, improved patient compliance, potentially lower treatment costs, and shorter time to BP control. Combination therapy has been recommended as potential first-line therapy in recent consensus guideline statements, especially for higher-risk patients, such as those with stage 2 hypertension. The combination of a renin-angiotensin-aldosterone system-targeting agent, such as an ACE inhibitor or angiotensin II receptor antagonist (ARB), and a diuretic or calcium channel antagonist appears to provide synergy with regard to BP lowering. In addition, ACE inhibitors and ARBs have demonstrated beneficial effects beyond BP reduction, reducing cardiovascular morbidity and mortality, inhibiting development and progression of type 2 diabetes mellitus and the progression of renal disease. Preliminary studies of fixed-dose combinations have shown reductions in left ventricular hypertrophy and improvements in markers of renal function. Additional studies currently underway will compare the effects of available fixed-dose combinations on cardiovascular morbidity and mortality, and markers of renal dysfunction.

show abstract

Efficacy of a Fixed-Dose Combination of Trandolapril-Verapamil in Obese Hypertensive Patients Resistant to Monotherapy

Rubio-Guerra

Lozano-Nuevo

Vargas-Ayala

et al. 2006

Clinical and Experimental Hypertension

View full text Add to dashboard Cite

This paper sought to determine if the fixed-dose combination of trandolapril and verapamil is effective in the treatment of hypertensive obese patients resistant to monotherapy. Thirty-six hypertensive obese patients uncontrolled by monotherapy were given the combination of trandolapril-verapamil (2/180 mg) for 12 weeks. Before and after taking the drug, they self-measured their blood pressure. Patients experienced a significant reduction of blood pressure (from 178 +/- 18/100 +/- 12 mm Hg to 135 +/- 14/76 +/- 7 mm Hg, p < 0.001). Eighty percent of patients reached therapeutic goals; one patient suffered from headaches and one had constipation. it was determined that the combination of trandolapril-verapamil is effective and safe for the management of hypertension in obese patients uncontrolled by monotherapy.

show abstract

Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and Hypertension

Cited by 12 publications

References 15 publications

Combination Therapy in the Treatment of Hypertension

Combination Therapy in the Treatment of Hypertension

Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage

Efficacy of a Fixed-Dose Combination of Trandolapril-Verapamil in Obese Hypertensive Patients Resistant to Monotherapy

Contact Info

Product

Resources

About